FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911332167> ?p ?o ?g. }

• W2911332167 endingPage "S254" @default.
• W2911332167 startingPage "S253" @default.
• W2911332167 abstract "BackgroundcGVHD is a major complication after allo-HSCT. The oral cavity is frequently affected and may present with painful ulcerations, intraoral discomfort, and limitation to oral intake. While systemic corticosteroids remain first line therapy for moderate/ severe cGVHD, topical and intralesional immunosuppressant (IS)-based therapies have been used with modest effect. PBM, a non-invasive light therapy, appears to promote tissue recovery via direct absorption of cytochrome C oxidase and activation of TGF-β1, and has been used for the prevention and treatment of radiation-induced mucositis in head & neck cancer. However, the effect of PBM therapy in oral cGVHD is currently unknown.MethodsWe evaluated 7 patients (median age 47) who underwent allo-HSCT (7 PBSC grafts) after myeloablative (n = 3) and reduced (n = 4) conditioning between 09/2015-05/2017. Patients developed moderate (n = 2) or severe (n = 5) oral cGVHD and received PBM (2x/week for 3 weeks) after failure to improve with topical corticosteroid and/or topical tacrolimus therapy +/- intralesional triamcinolone injections and systemic IS. Thor® laser LX2 with wavelengths of 660 nm (visible-red) and 810 nm (near-infrared) was applied extra-orally. The psychometric questionnaire for pain rating (Visual Analogue Scale [VAS], scale 0-10), and oral GVHD (OGVHD) score (severity of erythema, lichenoid changes, ulcers and mucoceles, scale 0-15) were used weekly for the assessment of therapeutic response.ResultsThe baseline oral cGVHD evaluation revealed high VAS (median 7, range 3-8) and OGVHD (median 9, range 6-9) scores. Patients had affected oral cavity that included lichen planus-like changes, ulcers, mucositis, gingivitis, and/or erythema (Fig. 1A-B). The first therapeutic response assessment was obtained 1 week after initiation of therapy and showed improvement in pain by VAS score (median 3). Subsequent assessments were obtained for the duration of PBM therapy and showed overall improvement in the pain scale and healing of the oral cavity (Fig. 1C-D, 2A-B). At the end of treatment, the median VAS score was 2 (range 1-2) and OGVHD was 3 (range 1-4). Treatment was well tolerated, and all patients received the intended number of PBM treatments in the planned period of 3 weeks. No adverse events were reported as related to PBM.ConclusionsAdvanced oral cGVHD achieved near-complete resolution of pain and oral cavity lesions after PBM therapy. Notable, patients who previously failed to respond to upfront topical and systemic IS treatment achieved high therapeutic response with PBM. Improvement in pain scale was observed 1 week after starting therapy and healing of the oral cavity was observed at 2 weeks. This non-IS treatment appears feasible, safe and promising in oral cGVHD. A prospective study is needed to confirm these preliminary findings. cGVHD is a major complication after allo-HSCT. The oral cavity is frequently affected and may present with painful ulcerations, intraoral discomfort, and limitation to oral intake. While systemic corticosteroids remain first line therapy for moderate/ severe cGVHD, topical and intralesional immunosuppressant (IS)-based therapies have been used with modest effect. PBM, a non-invasive light therapy, appears to promote tissue recovery via direct absorption of cytochrome C oxidase and activation of TGF-β1, and has been used for the prevention and treatment of radiation-induced mucositis in head & neck cancer. However, the effect of PBM therapy in oral cGVHD is currently unknown. We evaluated 7 patients (median age 47) who underwent allo-HSCT (7 PBSC grafts) after myeloablative (n = 3) and reduced (n = 4) conditioning between 09/2015-05/2017. Patients developed moderate (n = 2) or severe (n = 5) oral cGVHD and received PBM (2x/week for 3 weeks) after failure to improve with topical corticosteroid and/or topical tacrolimus therapy +/- intralesional triamcinolone injections and systemic IS. Thor® laser LX2 with wavelengths of 660 nm (visible-red) and 810 nm (near-infrared) was applied extra-orally. The psychometric questionnaire for pain rating (Visual Analogue Scale [VAS], scale 0-10), and oral GVHD (OGVHD) score (severity of erythema, lichenoid changes, ulcers and mucoceles, scale 0-15) were used weekly for the assessment of therapeutic response. The baseline oral cGVHD evaluation revealed high VAS (median 7, range 3-8) and OGVHD (median 9, range 6-9) scores. Patients had affected oral cavity that included lichen planus-like changes, ulcers, mucositis, gingivitis, and/or erythema (Fig. 1A-B). The first therapeutic response assessment was obtained 1 week after initiation of therapy and showed improvement in pain by VAS score (median 3). Subsequent assessments were obtained for the duration of PBM therapy and showed overall improvement in the pain scale and healing of the oral cavity (Fig. 1C-D, 2A-B). At the end of treatment, the median VAS score was 2 (range 1-2) and OGVHD was 3 (range 1-4). Treatment was well tolerated, and all patients received the intended number of PBM treatments in the planned period of 3 weeks. No adverse events were reported as related to PBM. Advanced oral cGVHD achieved near-complete resolution of pain and oral cavity lesions after PBM therapy. Notable, patients who previously failed to respond to upfront topical and systemic IS treatment achieved high therapeutic response with PBM. Improvement in pain scale was observed 1 week after starting therapy and healing of the oral cavity was observed at 2 weeks. This non-IS treatment appears feasible, safe and promising in oral cGVHD. A prospective study is needed to confirm these preliminary findings." @default.
• W2911332167 created "2019-02-21" @default.
• W2911332167 creator A5002737439 @default.
• W2911332167 creator A5045167741 @default.
• W2911332167 creator A5052956899 @default.
• W2911332167 creator A5056042755 @default.
• W2911332167 creator A5058746837 @default.
• W2911332167 creator A5066163702 @default.
• W2911332167 creator A5070096873 @default.
• W2911332167 creator A5085550690 @default.
• W2911332167 creator A5087158877 @default.
• W2911332167 date "2019-03-01" @default.
• W2911332167 modified "2023-09-26" @default.
• W2911332167 title "Photobiomodulation (PBM) Provides a Prompt and Near-Resolution Response to Advanced Oral Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)" @default.
• W2911332167 doi "https://doi.org/10.1016/j.bbmt.2018.12.255" @default.
• W2911332167 hasPublicationYear "2019" @default.
• W2911332167 type Work @default.
• W2911332167 sameAs 2911332167 @default.
• W2911332167 citedByCount "0" @default.
• W2911332167 crossrefType "journal-article" @default.
• W2911332167 hasAuthorship W2911332167A5002737439 @default.
• W2911332167 hasAuthorship W2911332167A5045167741 @default.
• W2911332167 hasAuthorship W2911332167A5052956899 @default.
• W2911332167 hasAuthorship W2911332167A5056042755 @default.
• W2911332167 hasAuthorship W2911332167A5058746837 @default.
• W2911332167 hasAuthorship W2911332167A5066163702 @default.
• W2911332167 hasAuthorship W2911332167A5070096873 @default.
• W2911332167 hasAuthorship W2911332167A5085550690 @default.
• W2911332167 hasAuthorship W2911332167A5087158877 @default.
• W2911332167 hasBestOaLocation W29113321671 @default.
• W2911332167 hasConcept C126322002 @default.
• W2911332167 hasConcept C141071460 @default.
• W2911332167 hasConcept C14184104 @default.
• W2911332167 hasConcept C16005928 @default.
• W2911332167 hasConcept C197934379 @default.
• W2911332167 hasConcept C2776201145 @default.
• W2911332167 hasConcept C2777408962 @default.
• W2911332167 hasConcept C2778496288 @default.
• W2911332167 hasConcept C2778903070 @default.
• W2911332167 hasConcept C2779972918 @default.
• W2911332167 hasConcept C2909675724 @default.
• W2911332167 hasConcept C2911091166 @default.
• W2911332167 hasConcept C509974204 @default.
• W2911332167 hasConcept C71924100 @default.
• W2911332167 hasConcept C90924648 @default.
• W2911332167 hasConceptScore W2911332167C126322002 @default.
• W2911332167 hasConceptScore W2911332167C141071460 @default.
• W2911332167 hasConceptScore W2911332167C14184104 @default.
• W2911332167 hasConceptScore W2911332167C16005928 @default.
• W2911332167 hasConceptScore W2911332167C197934379 @default.
• W2911332167 hasConceptScore W2911332167C2776201145 @default.
• W2911332167 hasConceptScore W2911332167C2777408962 @default.
• W2911332167 hasConceptScore W2911332167C2778496288 @default.
• W2911332167 hasConceptScore W2911332167C2778903070 @default.
• W2911332167 hasConceptScore W2911332167C2779972918 @default.
• W2911332167 hasConceptScore W2911332167C2909675724 @default.
• W2911332167 hasConceptScore W2911332167C2911091166 @default.
• W2911332167 hasConceptScore W2911332167C509974204 @default.
• W2911332167 hasConceptScore W2911332167C71924100 @default.
• W2911332167 hasConceptScore W2911332167C90924648 @default.
• W2911332167 hasIssue "3" @default.
• W2911332167 hasLocation W29113321671 @default.
• W2911332167 hasOpenAccess W2911332167 @default.
• W2911332167 hasPrimaryLocation W29113321671 @default.
• W2911332167 hasRelatedWork W1967911475 @default.
• W2911332167 hasRelatedWork W2009754503 @default.
• W2911332167 hasRelatedWork W2279261242 @default.
• W2911332167 hasRelatedWork W2884628875 @default.
• W2911332167 hasRelatedWork W2983332991 @default.
• W2911332167 hasRelatedWork W3029997219 @default.
• W2911332167 hasRelatedWork W3040563833 @default.
• W2911332167 hasRelatedWork W3167286380 @default.
• W2911332167 hasRelatedWork W4252631282 @default.
• W2911332167 hasRelatedWork W4304115271 @default.
• W2911332167 hasVolume "25" @default.
• W2911332167 isParatext "false" @default.
• W2911332167 isRetracted "false" @default.
• W2911332167 magId "2911332167" @default.
• W2911332167 workType "article" @default.